Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP... see more

Recent & Breaking News (CSE:BRAX)

Braxia Scientific Announces Closing of CAD$3 Million Private Placement

PR Newswire January 10, 2022

Braxia Scientific (CSE:BRAX) announces $3M private placement

John Ballem  January 7, 2022

Braxia Scientific Announces CAD$3 Million Private Placement with Institutional Investors

PR Newswire January 6, 2022

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

PR Newswire December 14, 2021

Braxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMD

PR Newswire November 9, 2021

Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami

PR Newswire November 8, 2021

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial

PR Newswire November 2, 2021

Braxia Scientific Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire October 29, 2021

Braxia Scientific Provides New Audio Webcast and Dial-In Number for Annual General Meeting

PR Newswire October 27, 2021

Braxia Scientific Featured in National News, W5 Canada's Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses

PR Newswire October 22, 2021

Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre

PR Newswire October 21, 2021

Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and 'Psychedelic Concierge' Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental Health

PR Newswire October 14, 2021

Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment

PR Newswire September 30, 2021

Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base

PR Newswire August 30, 2021

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression

PR Newswire August 27, 2021

Braxia Scientific Comments on US Class Action

PR Newswire August 27, 2021

Braxia Scientific Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

PR Newswire August 17, 2021

Braxia Scientific Announces Participation at Canaccord Genuity 2021 Annual Growth Conference August 10-12

PR Newswire August 6, 2021

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

PR Newswire July 30, 2021

Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality

PR Newswire July 28, 2021